Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 15;47(5):e20210157.
doi: 10.36416/1806-3756/e20210157. eCollection 2021.

Risk factors for recurrent wheezing in preterm infants who received prophylaxis with palivizumab

[Article in English, Portuguese]
Mariana Bueno Manini  1 , Natasha Yumi Matsunaga  1   2 , Lívea Gianfrancesco  1   2 , Marina Simões Oliveira  1   2 , Maria Rosa Vieira de Carvalho  3 , Gisleine Leila Martins Tengler Ribeiro  3 , Eliane de Oliveira Morais  3 , Maria Angela Gonçalves O Ribeiro  4 , André Moreno Morcillo  5 , José Dirceu Ribeiro  2   5 , Adyléia Aparecida Dalbo Contrera Toro  2   5
Affiliations

Risk factors for recurrent wheezing in preterm infants who received prophylaxis with palivizumab

[Article in English, Portuguese]
Mariana Bueno Manini et al. J Bras Pneumol. .

Abstract
in English, Portuguese

Objective: To determine the prevalence of recurrent wheezing (RW) in preterm infants who received prophylaxis against severe infection with respiratory syncytial virus (RSV) and to identify genetic susceptibility (atopy or asthma) and risk factors for RW.

Methods: This was a cross-sectional study involving preterm infants who received prophylaxis with palivizumab at a referral center in Brazil during the first two years of age. A structured questionnaire was administered in a face-to-face interview with parents or legal guardians.

Results: The study included 410 preterm infants (median age = 9 months [0-24 months]). In the sample as a whole, 111 children (27.1%; [95% CI, 22.9-31.5]) had RW. The univariate analysis between the groups with and without RW showed no differences regarding the following variables: sex, ethnicity, maternal level of education, gestational age, birth weight, breastfeeding, number of children in the household, day care center attendance, pets in the household, and smoking caregiver. The prevalence of RW was twice as high among children with bronchopulmonary dysplasia (adjusted OR = 2.08; 95% CI, 1.11-3.89; p = 0.022) and almost five times as high among those with a personal/family history of atopy (adjusted OR = 4.96; 95% CI, 2.62-9.39; p < 0.001) as among those without these conditions.

Conclusions: Preterm infants who received prophylaxis with palivizumab but have a personal/family history of atopy or bronchopulmonary dysplasia are more likely to have RW than do those without these conditions.

Objetivo:: Determinar a prevalência de sibilância recorrente (SR) em crianças pré-termo que receberam profilaxia contra infecção grave pelo vírus sincicial respiratório (VSR) e identificar susceptibilidade genética (atopia ou asma) e fatores de risco para SR.

Métodos:: Estudo transversal envolvendo crianças pré-termo que receberam profilaxia com palivizumabe em um centro de referência no Brasil durante os primeiros dois anos de vida. Um questionário estruturado foi aplicado em entrevista presencial com os pais ou responsáveis.

Resultados:: O estudo incluiu 410 crianças pré-termo (mediana de idade = 9 meses [0-24 meses]). Na amostra total, 111 crianças (27,1%; IC95%: 22,9-31,5) apresentavam SR. A análise univariada entre os grupos com e sem SR não mostrou diferenças em relação às seguintes variáveis: sexo, etnia, escolaridade materna, idade gestacional, peso ao nascer, aleitamento materno, número de crianças no domicílio, frequência em creche, presença de animais de estimação no domicílio e cuidador tabagista. A prevalência de SR foi duas vezes maior entre crianças com displasia broncopulmonar (OR ajustada = 2,08; IC95%: 1,11-3,89; p = 0,022) e quase cinco vezes maior entre aquelas com história pessoal/familiar de atopia (OR ajustada = 4,96; IC95%: 2,62-9,39; p < 0,001) do que entre aquelas sem essas condições.

Conclusões:: Crianças pré-termo que receberam profilaxia com palivizumabe, mas apresentam história pessoal/familiar de atopia ou displasia broncopulmonar, têm maior probabilidade de apresentar SR do que aquelas sem essas condições.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Flow chart of the participant selection process.
See this image and copyright information in PMC

References

    1. Mallol J, García-Marcos L, Solé D, Brand P. EISL Study Group International prevalence of recurrent wheezing during the first year of life variability, treatment patterns and use of health resources. Thorax. 2010;65(11):1004–1009. doi: 10.1136/thx.2009.115188. - DOI - PubMed
    1. Mallol J, Solé D, Garcia-Marcos L, Rosario N, Aguirre V, Chong H. Prevalence, Severity, and Treatment of Recurrent Wheezing During the First Year of Life A Cross-Sectional Study of 12,405 Latin American Infants. Allergy Asthma Immunol Res. 2016;8(1):22–31. doi: 10.4168/aair.2016.8.1.22. - DOI - PMC - PubMed
    1. Kwinta P, Pietrzyk JJ. Preterm birth and respiratory disease in later life. Expert Rev Respir Med. 2010;4(5):593–604. doi: 10.1586/ers.10.59. - DOI - PubMed
    1. Wu P, Hartert TV. Evidence for a causal relationship between respiratory syncytial virus infection and asthma. Expert Rev Anti Infect Ther. 2011;9(9):731–745. doi: 10.1586/eri.11.92. - DOI - PMC - PubMed
    1. Narayanan M, Owers-Bradley J, Beardsmore C, Mada M, Ball I, Garipov R. Alveolarization continues during childhood and adolescence new evidence from helium-3 magnetic resonance. Am J Respir Crit Care Med. 2012;185(2):186–191. doi: 10.1164/rccm.201107-1348OC. - DOI - PMC - PubMed

MeSH terms